Higgins John L's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed May 10, 2022
- Accession no.
- 0000886163-22-000060
- Filed
- May 10, 2022, 5:33 PM ET
- Trade date
- May 9-10, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 2 derivative transactions. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Higgins John LCIK 0001208906 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 9, 2022 | Common Stock | MOption exerciseAcquired | +8,000 | $21.92 | +$175,360 | 348,593 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 10, 2022 | 0.75% Convertible Senior Notes due 2023 | SSaleDisposed | – | $429,159.38 | – | – | Direct | Price outlier |
| May 9, 2022 | Common Stock | MOption exerciseDisposed | −8,000 | $0.00 | $0 | 57,616 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.